Nelson H. Slack

Learn More
In this clinical trial of men with advanced prostatic cancer no longer responsive to hormone therapy 189 were randomized to receive estramustine phosphate, methotrexate or cis-platinum. Response evaluations were done in 158 cases. Objective response rates (complete, partial or stabilization of disease) were 34 per cent for estramustine phosphate, 36 per(More)
Serum prostate-specific antigen and prostatic acid phosphatase were simultaneously evaluated in 22 healthy males, 29 patients with benign prostatic hypertrophy, and 192 patients with prostate cancers at various stages as well as in 30 patients with cancers other than prostate cancer. Both markers were quantitated by specific sandwich-type, enzyme-linked,(More)
Estramustine has been shown previously to be an effective drug in the treatment of metastatic prostatic cancer, demonstrating significant objective and subjective responses in long-term non-randomized trials and in other randomized trials. In this study prednimustine alone has shown a minimal over-all objective response rate of 12.9 percent of the cases,(More)
Results after 5 years of follow-up in a cooperative trial of therapies for operable bladder cancer confirmed preliminary indications of a beneficial effect of preoperative irradiation. Improved survival was experienced by the one-third of the irradiated patients who experienced complete eradication of the tumor as indicated from the resected specimen 30-60(More)
In 1958, a co-operative clinical trial, involving 23 institutions, was begun to evaluate the efficacy of a short course of triethylenethiophosphoramide as an adjuvant to radical mastectomy in the treatment of patients with primary carcinoma of the breast. Of 826 women prospectively randomized so that they received either a placebo or(More)
Criteria for evaluating response to therapy for both early and late stages of prostate cancer, as developed by the National Prostatic Cancer Project, are presented and discussed. Detection of bone metastases and monitoring of changes in existing bone lesions are critical to these criteria for early and late disease, respectively. The prognosis, or survival(More)